OpenAI Launches GPT-Rosalind for Drug Discovery and Biology

OpenAI on Friday, April 17, 2026, announced GPT-Rosalind, a specialized reasoning model built for life sciences research, drug discovery, and genomics. Named after British scientist Rosalind Franklin, who was instrumental in discovering DNA's structure, it is OpenAI's first model dedicated to biology. Qualified enterprise customers in the United States can access it as a research preview. Early partners include Amgen, Moderna, the Allen Institute, Thermo Fisher Scientific, and Novo Nordisk, whose partnership was separately announced on April 14.

A Model Tuned for Biology

GPT-Rosalind is designed to reason across molecules, proteins, genes, pathways, and disease-relevant biology, and to use scientific tools and databases for multi-step workflows including literature review, sequence-to-function interpretation, experimental planning, and data analysis. OpenAI said the model is intended to help compress a drug development timeline that in the United States typically runs 10 to 15 years from target discovery to regulatory approval. Access is gated behind a vetting process due to dual-use biosecurity concerns.

Altman and Bancel Frame the Launch

OpenAI CEO Sam Altman said: "AI is reshaping industries, and in life sciences, it can help people live better, longer lives." Moderna CEO Stéphane Bancel described the tool as a step forward for research teams: "GPT-Rosalind represents an important step in helping scientific teams use advanced AI to reason across complex biological evidence, data, and workflows." Bloomberg framed the launch as OpenAI entering a space where Google's Alphabet unit has led with AlphaFold and related tools.

A Limited, Vetted Rollout

The release is a research preview rather than a general-availability product, reflecting the careful posture OpenAI has adopted around biology models. Enterprise users must clear the company's vetting process, and further expansion will depend on how the preview plays out across the initial partner cohort.